The Tether™ - Vertebral Body Tethering System Post Approval Study
Launched by ZIMVIE · Aug 5, 2020
Trial Information
Current as of July 23, 2025
Recruiting
Keywords
ClinConnect Summary
The Tether™ - Vertebral Body Tethering System Post Approval Study is a clinical trial designed to gather important information about the safety and effectiveness of a treatment for idiopathic scoliosis, a condition where the spine curves abnormally. This study will focus on patients who have had a specific type of surgery called anterior vertebral body tethering (AVBT) using The Tether system. By collecting long-term data from these patients, researchers hope to confirm that this treatment is safe and beneficial for managing scoliosis.
To participate in this study, potential candidates must have progressive idiopathic scoliosis and be skeletally immature, meaning their bones are still growing. Specifically, they should have a curve in their spine that measures between 30° and 65° and have not found relief with bracing. Participants will need to attend follow-up visits to monitor their progress after surgery and must be willing to sign consent forms to join the study. This trial is currently recruiting participants of all ages and genders, and it aims to provide valuable insights for those affected by scoliosis.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Diagnosis of progressive idiopathic scoliosis
- • Skeletally immature, based on both Risser (\<5) and Sanders (\<8) assessments
- • Major Cobb angle ≥30° and ≤65°
- • Osseous structure dimensionally adequate to accommodate screw fixation, as determined by radiographic imaging
- • Failed or intolerant to bracing
- Exclusion Criteria:
- • Presence of any systemic infection, local infection, or skin compromise at the surgical site
- • Prior spinal surgery at the level(s) to be treated
- • Documented poor bone quality, defined as a T-score -1.5 or less
- • Any other medical or surgical condition which would preclude the potential benefit of spinal surgery, such as coagulation disorders, allergies to the implant materials, and patient's unwillingness or inability to cooperate with post-operative care instructions
- • Unwillingness, inability, or living situation (e.g. custody arrangements, homelessness, detention) that would preclude ability to return to the study site for follow-up visits as described in protocol and Informed Consent
- • Unwillingness to sign Informed Consent Form and participate in study procedures
About Zimvie
ZimVie is a pioneering medical technology company focused on advancing innovative solutions in the field of spine and dental health. With a commitment to enhancing patient outcomes, ZimVie develops and commercializes a diverse range of products, including implants, instruments, and biologics, designed to improve surgical procedures and overall quality of life. The company is dedicated to fostering research and development initiatives, collaborating with healthcare professionals to drive clinical trials that explore new therapeutic approaches and technologies. Through its dedication to excellence and innovation, ZimVie aims to lead the way in transforming patient care within the orthopedic and dental sectors.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Rochester, Minnesota, United States
Aurora, Colorado, United States
Atlanta, Georgia, United States
San Diego, California, United States
Seattle, Washington, United States
New York, New York, United States
New Orleans, Louisiana, United States
Columbia, Missouri, United States
Jacksonville, Florida, United States
Philadelphia, Pennsylvania, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials